FILING ANALYSIS · THURSDAY, NOVEMBER 5
Korro Bio, Inc. KRRO — 8-K: Termination of a Material Definitive Agreement
neutral
Korro Bio's collaboration and license agreement with Novo Nordisk has been terminated, but the company will retain its ownership interest in intellectual property and will not incur any early termination penalties, and separately, Korro reported a cash runway into the second half of 2028 and initiated dosing in its Phase 1/2 clinical trial for KRRO-121
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →